

Camlin Fine Chemicals Ltd.

Regd. Off: Plot No: F/11 & F/12, WICEL, Opp.SEEPZ Main Gate, Central Road, Andheri (E), Mumbai 400 093.

World's largest manufacturer of Food Antioxidants

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th SEPTEMBER, 2010.

(Rs. In Lacs)

Sr. No.	Particulars	UNAUDITED				AUDITED
		Quarter Ended		Half Year Ended		Year Ended
		30.09.2010	30.09.2009	30.09.2010	30.09.2009	31.03.2010
1	(a) Gross Sales/Income from Operations	3,704.30	2,951.72	6,828.55	5,555.91	12,603.11
	Less: Excise Duty	54.82	31.17	100.00	69.23	257.70
	Net Sales/Income from Operations	3,649.48	2,920.55	6,728.55	5,486.68	12,345.41
	(b) Other Operating Income	256.04	42.38	270.25	45.94	176.62
	Total Income (a+b)	3,905.52	2,962.93	6,998.80	5,532.62	12,522.03
2	Expenditure					
	a) (Increase)/Decrease in Stock in Trade & W.I.P	(79.01)	26.44	(507.71)	80.54	190.71
	b) Consumption of Raw Materials	2,482.11	1,628.55	4,785.90	3,123.49	6,704.93
	c) Purchase of Traded Goods	13.04	-	24.62	48.79	639.44
	d) Employees Cost	208.57	150.30	366.00	283.77	652.35
	e) Depreciation	131.03	92.61	257.24	208.61	442.59
	f) Other Expenditure	717.68	701.45	1,434.21	1,086.95	2,741.64
	g) Total Expenditure (a+b+c+d+e+f)	3,473.42	2,599.35	6,360.26	4,832.15	11,371.66
3	Profit from Operations before Other Income, Interest and Exceptional Item (1-2)	432.10	363.58	638.54	700.47	1,150.37
4	Other Income	51.53	11.87	112.05	21.65	111.91
5	Profit before Interest and Exceptional Items (3+4)	483.63	375.45	750.59	722.12	1,262.28
6	Interest	190.05	166.90	339.88	316.50	603.78
7	Profit after Interest but before Exceptional Items (5-6)	293.58	208.55	410.71	405.62	658.50
8	Exceptional Items	-	-	-	-	-
9	Profit from Ordinary Activities before tax (7+8)	293.58	208.55	410.71	405.62	658.50
10	Tax expenses	100.84	67.98	139.31	134.52	229.82
11	Profit from Ordinary Activities after tax (9-10)	192.74	140.57	271.40	271.10	428.68
12	Extraordinary item (net of tax expenses)	-	-	-	-	-
13	Net Profit for the period (11-12)	192.74	140.57	271.40	271.10	428.68
14	Paid-up Equity Share Capital (Face Value Rs.10/- per share)	930.27	580.00	930.27	580.00	581.45
15	Reserves excluding Revaluation Reserves (as per Balance Sheet of previous accounting year)					2,749.34
16	Earnings per Share (EPS)					
	Basic	2.07	2.42	2.92	4.66	7.39
	Diluted	2.20	1.68	3.17	3.24	7.30
17	Public Shareholding					
	Number of Shares	45,77,097	21,26,779	45,77,097	21,26,779	28,60,859
	Percentage of Shareholding	49.20	36.67	49.20	36.67	49.20
18	Promoters and promoter group Shareholding					
	a) Pledged / Encumbered					
	- Number of Shares	-	60,000	-	60,000	-
	- Percentage of share (as a % of the total shareholding of Promoter group)	-	1.63	-	1.63	-
	- Percentage of share (as a % of the total share capital of the Company)	-	1.03	-	1.03	-
	b) Non - Encumbered					
	- Number of Shares	47,25,591	36,13,221	47,25,591	36,13,221	29,53,621
	- Percentage of share (as a % of the total shareholding of Promoters & Promoter group)	100.00	98.37	100.00	98.37	100.00
	- Percentage of share (as a % of the total share capital of the Company)	50.80	62.30	50.80	62.30	50.80

Notes:

- The above results have been reviewed by the Statutory Auditor and the Audit Committee and have been taken on record at the meeting of the Board of Directors held on October 21, 2010.
- In the light of AS-17 Segmental Reporting, the Company operates in a single business segment namely "Fine Chemicals" and there is no reportable geographical segment.
- There were no Investor complaint pending at the beginning of the quarter. The Company did not receive any Investor complaint during the quarter.
- Pursuant to the Rights Issue, the Company has allotted 34,88,208 equity shares of Rs.10 each with share premium of Rs. 5.75 per equity share on 3rd September, 2010. Resultantly, the paid up capital as on the date of these financial statement now stands at Rs.930.27 Lacs.
- The proceeds of the aforesaid issue were to be utilised for meeting capital expenditure for development of plant processing and de-bottle necking and expenses of the issue. The Company has utilised Rs. 50.02 lacs out of the total proceeds of Rs. 549.39 lacs against capital expenditure and issue expenses. The balance funds are being utilised as working capital for the short term until the ultimate utilisation for the aforesaid purposes.
- Sangam Laboratories Limited has become a Wholly Owned Subsidiary Company as of 30th September, 2010.
- The figures of the previous period have been regrouped/ rearranged wherever necessary.

Statement of Assets & Liabilities (Unaudited)

(Rs. In Lacs)

Particulars	Current Period Ended 30.09.2010 (Unaudited)	Previous Accounting Year Ended 31.03.2010 (Audited)
Shareholders' Fund		
Capital	930.27	581.45
Reserves and Surplus	3,223.12	2,749.35
Loan Funds	5,208.75	4,036.95
Deferred Tax Liability	347.03	330.47
TOTAL	9,709.17	7,698.22
Fixed Assets (Net)	3,902.81	3,928.92
Investments	347.88	339.88
Current Assets, Loans and Advances		
a) Inventories	3,134.12	2,252.51
b) Sundry Debtors	3,793.87	3,295.76
c) Cash and Bank Balances	392.31	292.35
d) Loans and Advances	1,027.88	936.36
Less: Current Liabilities and Provisions		
a) Liabilities	2,716.04	3,065.34
b) Provisions	173.66	282.22
Miscellaneous Expenditure (to the extent not written off or adjusted)	-	-
TOTAL	9,709.17	7,698.22

By the Order of the Board

Place : Mumbai
Date : 21st October, 2010.

Ashish Dandekar
Managing Director

**Food Antioxidants - Polymer Stabilisers - Health and Pharmaceuticals
- Sweeteners - Bio-diesel Stabilisers - Rubber Stabilisers**